Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 67 of 1,261
  1. US 12208093

    Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)

    THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  2. CN 119365549

    Fluorescent probe targeting CA-IX

    BRACCO IMAGING SPA · Granted Jan 24, 2025 · Expires Jan 19, 2045

    granted
  3. WO 2025018295

    BACTÉRIOPHAGE MODIFIÉ

    ASTELLAS PHARMA INC [JP] · Granted Jan 23, 2025 · Expires Jan 18, 2045

    granted
  4. CN 119343336

    1, 4-bis-(2-hydroxy-benzyl)-1, 4, 7-triazacyclononane derivatives and similar compounds as ligands in iron (iii) complexes for use as MRI contrast agents

    BRACCO IMAGING SPA · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  5. US 12202797

    Method for producing pyrrole compound

    Takeda Pharmaceutical Company Limited · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  6. US 12201617

    HDAC6 inhibitors for treatment of metabolic disease and HFpEF

    Tenaya Therapeutics, Inc. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  7. US 12201591

    Sustained release compositions of endoxifen

    ATOSSA THERAPEUTICS, INC. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  8. US 12202902

    FLT3-specific chimeric antigen receptors and methods using same

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  9. US 12201673

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  10. US 12201699

    Compositions and methods for promoting homology directed repair

    Editas Medicine, Inc. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  11. US 12201598

    Immunoregulatory microparticles for modulating inflammatory arthritides

    The Regents of the University of California · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  12. US 12202895

    LILRB4 antibodies and uses thereof

    The Board of Regents of the University of Texas System · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  13. US 12201700

    Micro- and nano-device for cartilage injury detection and treatment

    The Board of Regents of the University of Texas System · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  14. US 12201719

    Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

    VACCINEX, INC. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  15. US 12203143

    Methods and kits to identify Klebsiella strains

    Arizona Board of Regents on Behalf of Northern Arizona University · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  16. US 12201604

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  17. US 12202883

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  18. US 12202832

    Heterocyclic compounds having a calcium-sensing receptor antagonistic activity

    Takeda Pharmaceutical Company Limited · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  19. US 12201639

    Aqueous oral pharmaceutical suspension compositions

    ReveraGen BioPharma, Inc. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  20. US 12201601

    Treatment for obesity

    AXSOME MALTA LTD. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  21. US 12201655

    Antimicrobial therapy

    The Regents of the University of California · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  22. US 12201593

    Oral pharmaceutical formulations of bitter compounds for asthma

    Aardvark Therapeutics, Inc. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  23. US 12203098

    Cells having solid tumor targeting backbone and use thereof

    Fate Therapeutics, Inc. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  24. US 12202901

    Cannabinoid receptor type 1 (CB1) antibodies, encoding nucleic acid molecules thereof and methods of use thereof

    Takeda Pharmaceutical Company Limited · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.